| Chaudhry et al. (2021)18 SR (1 RCT, Brisbe et al. 2014) |
EQ-5D score
Difference in EQ-5D score between IV iron group and oral iron group was not significant
Independence index score
Difference in independence index score between IV iron group and oral iron group was not significant
|
| Chaudhry et al. (2021)18 SR (1RCT, Yoo et al. 2019) |
EQ-5D score
Difference in EQ-5D score between IV iron group and control group was not significant
|
| Elhenawy et al. (2021)19 SR with MA (1 RCT, Bernabeu-Wittel et al. 2016) |
SF36v2 at 60 days post-hospital discharge reassessment for IV iron therapy versus control
Results showed statistically non-significant changes between groups (measurements NR)
|
| Elhenawy et al. (2021)19 SR with MA (1 RCT, Froessler et al. 2016) |
SF36 at 4 weeks post-surgery reassessment for IV iron therapy versus control
Results showed statistically non-significant changes between groups (measurements NR)
|
| Jones et al. (2021)20 SR (1 RCT, Khalafallah et al. 2016) |
SF36 scores from postoperative day 1 to postoperative week 12a
IV iron group = 13.4
Standard of care group = 9.1
Physical scores from postoperative day 1 to postoperative week 12a
IV iron group = 13.4
Standard of care group = 7.9
Mental scores from postoperative day 1 to postoperative week 12a
IV iron group = 13.3
Standard of care group = 9.9
|
| Jones et al. (2021)20 SR (1 RCT, Kim et al. 2017) |
Mean fatigue scores at week 3 (95% CI)a
IV iron group = 30 (26.8 to 33.1)
Placebo = 34.6 (31.3 to 37.9)
Mean dyspnea scores at week 12 (95% CI)a
IV iron group = 9.5 (7.2 to 11.8)
Placebo = 14.2 (11.3 to 17.1)
|
| Jones et al. (2021)20 SR (1 RCT, Richards et al. 2019) |
Mean EQ-5D-5L Utility scores at 10 days, 8 weeks, and 6 months postoperative (SD)a
IV iron group = 0.80 (0.20); 0.79 (0.20); 0.82 (0.22)
Placebo group = 0.81 (0.21); 0.77 (0.21); 0.82 (0.21)
Mean EQ-5D-5L Health scores at 10 days, 8 weeks, and 6 months postoperative (SD)a
IV iron group = 70.6 (20.5); 70.7 (19.4); 75.0 (18.4)
Placebo group = 73.8 (19.6); 71.1 (19.5); 76.2 (19.2)
Mean MFI scores at 10 days, 8 weeks, and 6 months postoperative (SD)a
IV iron group = 53.2 (18.4); 52.9 (17.1); 48.8 (18.9)
Placebo group = 50.5 (18.9); 53.9 (17.7); 47.4 (19.1)
|
| Fung et al. (2022)22 RCT |
Median QOR-15 score (range)
IV iron group = 107 (100 to 124)
Control group = 115 (103 to 125)
P = 0.547
|
| Kvaslerud et al. (2022)23 RCT |
Mean EQ-5D3L index scores between IV iron group and placebo group at baseline and follow-up (range)
Mean IV iron group scores at baseline = 0.83 (0.77 to 0.93); Mean IV iron group scores at follow-up = 0.91 (0.82 to 0.97)
Mean placebo group scores at baseline = 0.81 (0.74 to 0.93); Mean placebo group scores at follow-up = 0.91 (0.78 to 0.97)
Mean difference (95% CI) = -0.001 (-0.4 to 0.4); P = 0.97
Mean EQ-5D VAS scores between IV iron group and placebo group at baseline and follow-up (range)
Mean IV iron group scores at baseline = 67 (50 to 80); Mean IV iron group scores at follow-up = 70 (48 to 84)
Mean placebo group scores at baseline = 50 (40 to 73); Mean placebo group scores at follow-up = 75 (60 to 85)
Mean difference (95% CI) = -7.8 (-16.5 to 0.86); P = 0.077
|
| Thin et al. (2021)25 RCT |
Mean EQ-5D-3L score at baseline between IV iron group (N = 15) and oral iron group (N = 15) (SD)
IV iron group = 70.3 (22)
Oral iron group = 73 (8)
P = 0.6
Mean EQ-5D-3L score at 1 month follow-up between IV iron group (N = 13) and oral iron group (N = 11) (SD)
IV iron group = 70.4 (21.8)
Oral iron group = 84.5 (12.1)
P = 0.07
Mean EQ-5D-3L score at 3-month follow-up between IV iron group (N = 13) and oral iron group (N = 11) (SD)
IV iron group = 80 (18.4)
Oral iron group = 85.9 (10.7)
P = 0.4
|
